Wealth Enhancement Advisory Services LLC Acquires 80,000 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Wealth Enhancement Advisory Services LLC lifted its position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 160.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 130,000 shares of the company’s stock after buying an additional 80,000 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.36% of Checkpoint Therapeutics worth $291,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in shares of Checkpoint Therapeutics in the second quarter worth $34,000. Magnus Financial Group LLC boosted its holdings in Checkpoint Therapeutics by 12.9% in the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares during the last quarter. 180 Wealth Advisors LLC bought a new stake in Checkpoint Therapeutics in the second quarter valued at approximately $96,000. Choreo LLC boosted its holdings in Checkpoint Therapeutics by 12.2% in the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after acquiring an additional 7,080 shares during the last quarter. Finally, PVG Asset Management Corp bought a new position in shares of Checkpoint Therapeutics during the 2nd quarter worth approximately $295,000. Institutional investors and hedge funds own 22.00% of the company’s stock.

Checkpoint Therapeutics Stock Performance

Shares of CKPT opened at $3.37 on Monday. The business has a 50-day moving average of $2.69 and a 200 day moving average of $2.28. Checkpoint Therapeutics, Inc. has a fifty-two week low of $1.36 and a fifty-two week high of $3.97. The firm has a market cap of $151.71 million, a P/E ratio of -1.77 and a beta of 1.23.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Monday, August 12th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.11. The company had revenue of $0.04 million during the quarter. As a group, research analysts predict that Checkpoint Therapeutics, Inc. will post -0.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a report on Monday, September 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.